The DOI matches its Crossref record; 147 of the 147 references it cites were found in a registry or an index.
Mechanisms and insights into drug resistance in cancer
Open accessAbstract
Cancer drug resistance continues to be a major impediment in medical oncology. Clinically, resistance can arise prior to or as a result of cancer therapy. In this review, we discuss different mechanisms adapted by cancerous cells to resist treatment, including alteration in drug transport and metabolism, mutation and amplification of drug targets, as well as genetic rewiring which can lead to impaired apoptosis. Tumor heterogeneity may also contribute to resistance, where small subpopulations of cells may acquire or stochastically already possess some of the features enabling them to emerge under selective drug pressure. Making the problem even more challenging, some of these resistance pathways lead to multidrug resistance, generating an even more difficult clinical problem to overcome. We provide examples of these mechanisms and some insights into how understanding these processes can influence the next generation of cancer therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
A human colon cancer cell capable of initiating tumour growth in immunodeficient mice
O’Brien, C. A., Pollett, A., Gallinger, S., & Dick, J. E. (2007) · Nature · doi:10.1038/nature05372 · Cited by 4,087
Identification and expansion of human colon-cancer-initiating cells
Ricci-Vitiani, L., Lombardi, D. G., Pilozzi, E., Biffoni, M., Todaro, M., Peschle, C., & De Maria, R. (2007) · Nature · doi:10.1038/nature05384 · Cited by 3,998
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Cancer treatment and survivorship statistics, 2022
Miller, K. D., Nogueira, L., Devasia, T., Mariotto, A. B., Yabroff, K. R., Jemal, A., Kramer, J., & Siegel, R. L. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21731 · Cited by 3,597
O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T., Hochhaus, A., Hughes, T., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022457 · Cited by 3,570
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · cited 1×
“…at the gatekeeper residues of the kinase domain which disables drug binding (Gorre et al., 2001; Blencke et al., 2003; Kobayashi et al., 2005; Pao et al., 2005; Soverini et al., 2005; Balak et al., 2006; Jabbour et al., 2006, 2008; Nicolini et al., 2006; Apperley, 2007; Costa et al., 2007;…”
BackgroundStratton, M. R., Campbell, P. J., & Futreal, P. A. (2009) · Nature · doi:10.1038/nature07943 · Cited by 3,449
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Cancer treatment and survivorship statistics, 2012
Siegel, R., DeSantis, C., Virgo, K., Stein, K., Mariotto, A., Smith, T., Cooper, D., Gansler, T., Lerro, C., Fedewa, S., et al. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21149 · Cited by 2,928
Mechanisms of Cancer Drug Resistance
Gottesman, M. M. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103929 · Cited by 2,643
Genomic instability — an evolving hallmark of cancer
Negrini, S., Gorgoulis, V. G., & Halazonetis, T. D. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2858 · Cited by 2,397
International network of cancer genome projects
The International Cancer Genome Consortium (2010) · Nature · doi:10.1038/nature08987 · Cited by 2,299
Principles of cancer therapy: oncogene and non-oncogene addiction
Luo, J., Solimini, N. L., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.02.024 · Cited by 1,765
A family of drug transporters: the multidrug resistance-associated proteins
Borst, P., Evers, R., Kool, M., & Wijnholds, J. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.16.1295 · Cited by 1,751
Addiction to Oncogenes--the Achilles Heal of Cancer
Weinstein, I. B. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,728
Tumor heterogeneity: Causes and consequences
Marusyk, A., & Polyak, K. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.11.002 · Cited by 1,602
Hallmarks of Cancer: The Next Generation
Roizen, M. F. (2012) · Yearbook of Anesthesiology and Pain Management · doi:10.1016/j.yane.2012.02.046 · Cited by 1,501
Weaver, V. M., Petersen, O. W., Wang, F., Larabell, C. A., Briand, P., Damsky, C., & Bissell, M. J. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.137.1.231 · Cited by 1,483
Hughes, T. P., Kaeda, J., Branford, S., Rudzki, Z., Hochhaus, A., Hensley, M. L., Gathmann, I., Bolton, A. E., van Hoomissen, I. C., Goldman, J. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030513 · Cited by 1,218
Lamon, D. E. J. S., Eyland, B. R. L., Hak, S. T. S., Uchs, H. A. F., Aton, V. I. P., Ajamonde, A. L. B., LeMing, T., Iermann, W. O. E., Olter, J. A. W., Egram, M. A. P., et al. (2009) · Cited by 1,199
Cancer stem cells: an evolving concept
Nguyen, L. V., Vanner, R., Dirks, P., & Eaves, C. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3184 · Cited by 1,171
Sawyers, C. (2004) · Nature · doi:10.1038/nature03095 · Cited by 1,165
Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment
Goldman, J. M., & Melo, J. V. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020777 · Cited by 950
Environment-mediated drug resistance: A major contributor to minimal residual disease
Meads, M. B., Gatenby, R. A., & Dalton, W. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2714 · Cited by 892
Smoothened Mutation Confers Resistance to a Hedgehog Pathway Inhibitor in Medulloblastoma
Yauch, R. L., Dijkgraaf, G. J. P., Alicke, B., Januario, T., Ahn, C. P., Holcomb, T., Pujara, K., Stinson, J., Callahan, C. A., Tang, T., et al. (2009) · Science · doi:10.1126/science.1179386 · Cited by 839
Balak, M. N., Gong, Y., Riely, G. J., Somwar, R., Li, A. R., Zakowski, M. F., Chiang, A., Yang, G., Ouerfelli, O., Kris, M. G., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1570 · Cited by 824
Campbell, P. J., Stephens, P. J., Pleasance, E. D., O'Meara, S., Li, H., Santarius, T., Stebbings, L. A., Leroy, C., Edkins, S., Hardy, C., et al. (2008) · Nature Genetics · doi:10.1038/ng.128 · Cited by 824
Principles for the Buffering of Genetic Variation
Hartman IV, J. L. (2001) · Science · doi:10.1126/science.291.5506.1001 · Cited by 808
Principles for the buffering of genetic variation
Hartman, J. L., Garvik, B., & Hartwell, L. (2001) · Science · doi:10.1126/science.1056072 · Cited by 808
König, J., Nies, A. T., Cui, Y., Leier, I., & Keppler, D. (1999) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(99)00169-8 · Cited by 791
The Dawn of Darwinian Medicine
Williams, G. C., & Nesse, R. M. (1991) · The Quarterly Review of Biology · doi:10.1086/417048 · Cited by 745
Aas, T., Børresen, A.-L., Geisler, S., Smith-Sørensen, B., Johnsen, H., Varhaug, J. E., Akslen, L. A., & Lønning, P. E. (1996) · Nature Medicine · doi:10.1038/nm0796-811 · Cited by 736
Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy
Weinstein, I. B., & Joe, A. K. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0558 · Cited by 705
The Stem Cell Marker Bcrp/ABCG2 Enhances Hypoxic Cell Survival through Interactions with Heme
Krishnamurthy, P., Ross, D. D., Nakanishi, T., Bailey-Dell, K., Zhou, S., Mercer, K. E., Sarkadi, B., Sorrentino, B. P., & Schuetz, J. D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313599200 · Cited by 661
Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia
Apperley, J. F. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70342-x · Cited by 643
Intestinal stem cells protect their genome by selective segregation of template DNA strands
Potten, C. S., Owen, G., & Booth, D. (2002) · Journal of Cell Science · doi:10.1242/jcs.115.11.2381 · Cited by 633
Overexpression of Metallothionein Confers Resistance to Anticancer Drugs
Kelley, S. L., Basu, A., Teicher, B. A., Hacker, M. P., Hamer, D. H., & Lazo, J. S. (1988) · Science · doi:10.1126/science.3175622 · Cited by 601
BindingDB (2013) · PubMed · doi:10.7270/q2q81fck · Cited by 571
Matsunaga, T., Takemoto, N., Sato, T., Takimoto, R., Tanaka, I., Fujimi, A., Akiyama, T., Kuroda, H., Kawano, Y., Kobune, M., et al. (2003) · Nature Medicine · doi:10.1038/nm909 · Cited by 563
Interferon Alfa-2b Combined with Cytarabine versus Interferon Alone in Chronic Myelogenous Leukemia
Guilhot, F., Chastang, C., Michallet, M., Guerci, A., Harousseau, J.-L., Maloisel, F., Bouabdallah, R., Guyotat, D., Cheron, N., Nicolini, F., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707243370402 · Cited by 543
Ishikawa, T., & Ali-Osman, F. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)80702-9 · Cited by 533
Nucleoside analogues: mechanisms of drug resistance and reversal strategies
Galmarini, C., Mackey, Jr., & Dumontet, C. (2001) · Leukemia · doi:10.1038/sj.leu.2402114 · Cited by 511
Costa, D. B., Halmos, B., Kumar, A., Schumer, S. T., Huberman, M. S., Boggon, T. J., Tenen, D. G., & Kobayashi, S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040315 · Cited by 499
le Coutre, P., Tassi, E., Varella-Garcia, M., Barni, R., Mologni, L., Cabrita, G., Marchesi, E., Supino, R., & Gambacorti-Passerini, C. (2000) · Blood · doi:10.1182/blood.v95.5.1758.005a41_1758_1766 · Cited by 484
Juvekar, A., Burga, L. N., Hu, H., Lunsford, E. P., Ibrahim, Y. H., Balmañà, J., Rajendran, A., Papa, A., Spencer, K., Lyssiotis, C. A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0336 · Cited by 465
Inukai, M., Toyooka, S., Ito, S., Asano, H., Ichihara, S., Soh, J., Suehisa, H., Ouchida, M., Aoe, K., Aoe, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1951 · Cited by 452
Oncogene addiction: setting the stage for molecularly targeted cancer therapy
Sharma, S. V., & Settleman, J. (2007) · Genes & Development · doi:10.1101/gad.1609907 · Cited by 441
The Emperor of All Maladies: A Biography of Cancer
Mukherjee, S. (2010) · Cited by 416
Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity.
Xu, Y., & Villalona-Calero, M. A. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf337 · Cited by 413
White, D. E., Kurpios, N. A., Zuo, D., Hassell, J. A., Blaess, S., Mueller, U., & Muller, W. J. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.025 · Cited by 413
Structural, mechanistic and clinical aspects of MRP1
Hipfner, D. R., Deeley, R. G., & Cole, S. P. C. (1999) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(99)00168-6 · Cited by 412
Acute promyelocytic leukemia: evolving therapeutic strategies
Tallman, M. S., Nabhan, C., Feusner, J. H., & Rowe, J. M. (2002) · Blood · doi:10.1182/blood.v99.3.759 · Cited by 398
Braun, S., Kentenich, C., Janni, W., Hepp, F., de Waal, J., Willgeroth, F., Sommer, H., & Pantel, K. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.80 · Cited by 394
Jabbour, E., Kantarjian, H., Jones, D., Talpaz, M., Bekele, N., O'Brien, S., Zhou, X., Luthra, R., Garcia-Manero, G., Giles, F., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404318 · Cited by 386
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Hanna, N. H. (2008) · Yearbook of Oncology · doi:10.1016/s1040-1741(08)79219-4 · Cited by 386
Peto's Paradox: evolution's prescription for cancer prevention
Caulin, A. F., & Maley, C. C. (2011) · Trends in Ecology & Evolution · doi:10.1016/j.tree.2011.01.002 · Cited by 384
Soverini, S., Martinelli, G., Rosti, G., Bassi, S., Amabile, M., Poerio, A., Giannini, B., Trabacchi, E., Castagnetti, F., Testoni, N., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.531 · Cited by 374
Molecular Signatures of Proliferation and Quiescence in Hematopoietic Stem Cells
Venezia, T. A., Merchant, A. A., Ramos, C. A., Whitehouse, N. L., Young, A. S., Shaw, C. A., & Goodell, M. A. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020301 · Cited by 362
Hazlehurst, L. A., Damiano, J. S., Buyuksal, I., Pledger, W. J., & Dalton, W. S. (2000) · Oncogene · doi:10.1038/sj.onc.1203782 · Cited by 344
Taron, M., Ichinose, Y., Rosell, R., Mok, T., Massuti, B., Zamora, L., Mate, J. L., Manegold, C., Ono, M., Queralt, C., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2618 · Cited by 334
FREI, E., KARON, M., LEVIN, R. H., FREIREICH, E. J., TAYLOR, R. J., HANANIAN, J., SELAWRY, O., HOLLAND, J. F., HOOGSTRATEN, B., WOLMAN, I. J., et al. (1965) · Blood · doi:10.1182/blood.v26.5.642.642 · Cited by 325
Synthetic lethality: General principles, utility and detection using genetic screens in human cells
Nijman, S. M. B. (2011) · FEBS Letters · doi:10.1016/j.febslet.2010.11.024 · Cited by 319
Damaraju, V. L., Damaraju, S., Young, J. D., Baldwin, S. A., Mackey, J., Sawyer, M. B., & Cass, C. E. (2003) · Oncogene · doi:10.1038/sj.onc.1206952 · Cited by 318
Immunotoxins for targeted cancer therapy
Kreitman, R. J. (2006) · The AAPS Journal · doi:10.1208/aapsj080363 · Cited by 307
Collateral sensitivity as a strategy against cancer multidrug resistance
Pluchino, K. M., Hall, M. D., Goldsborough, A. S., Callaghan, R., & Gottesman, M. M. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.03.002 · Cited by 305
Translating insights from the cancer genome into clinical practice
Chin, L., & Gray, J. W. (2008) · Nature · doi:10.1038/nature06914 · Cited by 300
Tankyrase-targeted therapeutics: expanding opportunities in the PARP family
Riffell, J. L., Lord, C. J., & Ashworth, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3868 · Cited by 285
Castells, M., Thibault, B., Delord, J.-P., & Couderc, B. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13089545 · Cited by 285
Heterogeneity in drug sensitivity among tumor cell subpopulations of a single mammary tumor.
Heppner, G. H., Dexter, D. L., DeNucci, T., Miller, F. R., & Calabresi, P. A. (1978) · PubMed · Cited by 280
Bean, J., Riely, G. J., Balak, M., Marks, J. L., Ladanyi, M., Miller, V. A., & Pao, W. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0151 · Cited by 278
Interferon-α and cancer: Mechanisms of action and new perspectives of clinical use
Ferrantini, M., Capone, I., & Belardelli, F. (2007) · Biochimie · doi:10.1016/j.biochi.2007.04.006 · Cited by 268
Kummar, S., Chen, A., Ji, J., Zhang, Y., Reid, J. M., Ames, M., Jia, L., Weil, M., Speranza, G., Murgo, A. J., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1227 · Cited by 259
Is resistance useless? Multidrug resistance and collateral sensitivity
Hall, M. D., Handley, M. D., & Gottesman, M. M. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.07.003 · Cited by 259
Evolutionary biology of cancer
Crespi, B., & Summers, K. (2005) · Trends in Ecology & Evolution · doi:10.1016/j.tree.2005.07.007 · Cited by 259
(1992) · Lung Cancer · doi:10.1016/0169-5002(92)90185-m · Cited by 237
Genomic instability and cancer: an introduction
Shen, Z. (2011) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjq057 · Cited by 229 · cited 1×
“The second mechanism involves the acquisition of stochastic alterations within the cancer cells which provide a survival advantage (Campbell et al., 2008; Stratton et al., 2009; Negrini et al., 2010; The International Cancer Genome Consortium, 2010; Shen, 2011).”
BackgroundAntisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells.
Arber, N., Doki, Y., Han, E. K.-H., Sgambato, A., Zhou, P., Kim, N. H., Delohery, T. M., Klein, M. G., Holt, P. R., & Weinstein, I. B. (1997) · PubMed · Cited by 226
The Emperor of All Maladies: A Biography of Cancer
Mehta, P. (2011) · JAMA · doi:10.1001/jama.2011.798 · Cited by 225
Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds.
Meijer, C., Mulder, N. H., Timmer‐Bosscha, H., Sluiter, W. J., Meersma, G. J., & de Vries, E. G. E. (1992) · PubMed · Cited by 216
The Origins and Implications of Intratumor Heterogeneity
Michor, F., & Polyak, K. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0234 · Cited by 209
Nicolini, F. E., Corm, S., Lê, Q.-H., Sorel, N., Hayette, S., Bories, D., Leguay, T., Roy, L., Giraudier, S., Tulliez, M., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404236 · Cited by 207
Erlotinib in-Previously Treated Non-Small-Cell Lung Cancer
Hanna, N. H. (2006) · Yearbook of Oncology · doi:10.1016/s1040-1741(08)70163-5 · Cited by 207
Anti-Apoptotic Mechanisms of Drug Resistance in Cancer
Wilson, T., Johnston, P., & Longley, D. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909788166547 · Cited by 203
Shain, K. H., Yarde, D. N., Meads, M. B., Huang, M., Jove, R., Hazlehurst, L. A., & Dalton, W. S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2419 · Cited by 200
Thomas, D. A., Kantarjian, H., Smith, T. L., Koller, C., Cortes, J., O'Brien, S., Giles, F. J., Gajewski, J., Pierce, S., & Keating, M. J. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19991001)86:7<1216::aid-cncr17>3.0.co;2-o · Cited by 196
Nobili, S., Landini, I., Mazzei, T., & Mini, E. (2012) · Medicinal Research Reviews · doi:10.1002/med.20239 · Cited by 182
Darwinian medicine: a case for cancer
Greaves, M. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2071 · Cited by 180
Cancer multidrug resistance (MDR): a major impediment to effective chemotherapy.
Ullah, M. F. (2009) · PubMed · Cited by 180
Overview of Tumor Cell Chemoresistance Mechanisms
Gatti, L., & Zunino, F. (2005) · Chemosensitivity · doi:10.1385/1-59259-889-7:127 · Cited by 179
Mori, Y., Shimizu, N., Dallas, M., Niewolna, M., Story, B., Williams, P. J., Mundy, G. R., & Yoneda, T. (2004) · Blood · doi:10.1182/blood-2004-01-0236 · Cited by 176
Targeting Bcl-2 and Bcl-X with nonpeptidic small-molecule antagonists
WANG, S. (2003) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.08.015 · Cited by 175
Kelly, R. J., Draper, D., Chen, C. C., Robey, R. W., Figg, W. D., Piekarz, R. L., Chen, X., Gardner, E. R., Balis, F. M., Venkatesan, A. M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1725 · Cited by 172
Borsellino, N., Belldegrun, A. S., & Bonavida, B. (1995) · PubMed · Cited by 171
Chemoresistance in solid tumours
Wilson, T. R., Longley, D. B., & Johnston, P. G. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl280 · Cited by 170
Cai, J., Weiss, M. L., & Rao, M. S. (2004) · Experimental Hematology · doi:10.1016/j.exphem.2004.03.013 · Cited by 167
DNA Repair Defects in Stem Cell Function and Aging
Park, Y., & Gerson, S. L. (2005) · Annual Review of Medicine · doi:10.1146/annurev.med.56.082103.104546 · Cited by 167
Sampath, D., Cortes, J., Estrov, Z., Du, M., Shi, Z., Andreeff, M., Gandhi, V., & Plunkett, W. (2005) · Blood · doi:10.1182/blood-2005-08-3351 · Cited by 160
Frassanito, M. A., Cusmai, A., Iodice, G., & Dammacco, F. (2001) · Blood · doi:10.1182/blood.v97.2.483 · Cited by 159
Shen, C., Yu, J.-C., Lo, Y.-L., Kuo, C. H., Yue, C. T., Jou, Y., Huang, C., Lung, J. C., & Wu, C.-H. (2000) · PubMed · Cited by 158
Natalizumab: Targeting α4-Integrins in Multiple Sclerosis
Engelhardt, B., & Kappos, L. (2007) · Neurodegenerative Diseases · doi:10.1159/000109933 · Cited by 157
Advances in using PARP inhibitors to treat cancer
Kummar, S., Chen, A. P., Parchment, R. E., Kinders, R. J., Ji, J., Tomaszewski, J. E., & Doroshow, J. H. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-25 · Cited by 151
International Cancer Genome Consortium
Berger, D. (2013) · Im Focus Onkologie · doi:10.1007/s15015-013-0268-6 · Cited by 148
Jabbour, E. J., Kantarjian, H. M., Jones, D. M., Breeden, M., Garcia‐Manero, G., O'Brien, S. M., Ravandi, F., Borthakur, G. M., & Cortes, J. E. (2008) · Blood · doi:10.1182/blood-2007-11-123950 · Cited by 147
Bidard, F., Vincent‐Salomon, A., Gomme, S., Nos, C., Rycke, Y. D., Thiery, J. P., Sigal‐Zafrani, B., Mignot, L., Sastre‐Garau, X., Pierga, J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4749 · Cited by 142
ABT-888 Confers Broad In vivo Activity in Combination with Temozolomide in Diverse Tumors
Palma, J. P., Wang, Y., Rodriguez, L. E., Montgomery, D., Ellis, P. A., Bukofzer, G. T., Niquette, A. L., Liu, X., Shi, Y., Lasko, L. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1245 · Cited by 142
Hazlehurst, L. A., Enkemann, S. A., Beam, C. A., Argilagos, R. F., Painter, J. S., Shain, K. H., Saporta, S., Boulware, D. C., Moscinski, L. C., Alsina, M., et al. (2003) · PubMed · Cited by 138
Hazlehurst, L., Valkov, N. I., Wisner, L., Storey, J. A., Boulware, D. C., Sullivan, D. M., & Dalton, W. S. (2001) · Blood · doi:10.1182/blood.v98.6.1897 · Cited by 132
Hofmann, W., Komor, M., Waßmann, B., Jones, L. C., Gschaidmeier, H., Hoelzer, D. F., Koeffler, H. P., & Ottmann, O. G. (2003) · Blood · doi:10.1182/blood-2002-06-1756 · Cited by 124
Shain, K. H., Landowski, T. H., & Dalton, W. S. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.5.2544 · Cited by 122
EGFRMutation and Response of Lung Cancer to Gefitinib
Toyooka, S., Kiura, K., & Mitsudomi, T. (2005) · New England Journal of Medicine · doi:10.1056/nejm200505193522019 · Cited by 119
Hedgehog pathway inhibition and the race against tumor evolution
Atwood, S. X., Chang, A. L. S., & Oro, A. E. (2012) · The Journal of Cell Biology · doi:10.1083/jcb.201207140 · Cited by 118
Voorhees, P. M., Chen, Q., Kuhn, D. J., Small, G. W., Hunsucker, S. A., Strader, J. S., Corringham, R. E., Zaki, M. H., Nemeth, J. A., & Orlowski, R. Z. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1293 · Cited by 118
Blencke, S., Ullrich, A., & Daub, H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211158200 · Cited by 117
Trudeau, M., Crump, M., Charpentier, D., Yelle, L., Bordeleau, L. J., Matthews, S. W., & Eisenhauer, E. A. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl056 · Cited by 113
Resistance to PARP-Inhibitors in Cancer Therapy
Montoni, A., Robu, M., Pouliot, É., & Shah, G. M. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00018 · Cited by 112
The evolutionary origin of genetic instability in cancer development
Breivik, J. (2004) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2004.09.008 · Cited by 112
PARP inhibitors stumble in breast cancer
Guha, M. (2011) · Nature Biotechnology · doi:10.1038/nbt0511-373 · Cited by 110
Croix, B. S., Rak, J. W., Kapitain, S. J., Sheehan, C., Graham, C. H., & Kerbel, R. S. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.18.1285 · Cited by 107
Lwin, T., Hazlehurst, L., Dessureault, S., Lai, R. L., Bai, W., Sotomayor, E. M., Moscinski, L. C., Dalton, W. S., & Tao, J. (2007) · Blood · doi:10.1182/blood-2006-11-060350 · Cited by 104
Longo-Sorbello, G. S. A., & Bertino, J. R. (2001) · PubMed · Cited by 92
Borsellino, N., Bonavida, B., Ciliberto, G., Toniatti, C., Travali, S., & D’Alessandro, N. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990101)85:1<134::aid-cncr19>3.0.co;2-c · Cited by 84
Hazlehurst, L., Argilagos, R. F., & Dalton, W. S. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06435.x · Cited by 82
Current Status of Methods to Assess Cancer Drug Resistance
Lippert, T. H., Ruoff, H. J., & Volm, M. (2011) · International Journal of Medical Sciences · doi:10.7150/ijms.8.245 · Cited by 81
Wong, A. L., & Lee, S. C. (2012) · International Journal of Breast Cancer · doi:10.1155/2012/415170 · Cited by 80
Cancer stem cell hypothesis in thyroid cancer
Zhang, P., Zuo, H., Ozaki, T., Nakagomi, N., & Kakudo, K. (2006) · Pathology International · doi:10.1111/j.1440-1827.2006.01995.x · Cited by 70
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2007) · Nature · doi:10.1038/nature05789 · Cited by 70
A Blueprint for Advancing Genetics-Based Cancer Therapy
Sellers, W. R. (2011) · Cell · doi:10.1016/j.cell.2011.09.016 · Cited by 66
How is Darwinian medicine useful?
Nesse, R. M. (2001) · Western Journal of Medicine · doi:10.1136/ewjm.174.5.358 · Cited by 58
Palma, J. P., Rodriguez, L. E., Bontcheva-Diaz, V., Bouska, J. J., Bukofzer, G. T., Colón-López, M. S., Guan, R., Jarvis, K., Johnson, E. F., Klinghofer, V., et al. (2008) · PubMed · Cited by 56
O’Connor, D., Sibson, K. R., Caswell, M., Connor, P., Cummins, M., Mitchell, C., Motwani, J., Taj, M., Vora, A. J., Wynn, R. F., et al. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08752.x · Cited by 50
Wild, P. J., Knuechel, R., Dietmaier, W., et al. (2000) · Pathobiology · doi:10.1159/000055921 · Cited by 47
A snapshot of chemoresistance to PARP inhibitors
Chiarugi, A. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.10.001 · Cited by 43
Robertson, J. D. (2006) · Shock · doi:10.1097/01.shk.0000248599.09507.90 · Cited by 40
On evolutionary origin of cancer.
Lichtenstein, A. V. (2005) · Cancer Cell International · doi:10.1186/1475-2867-5-5 · Cited by 33
Isoyama, S., Dan, S., Nishimura, Y. H., Nakamura, N., Kajiwara, G., Seki, M., Irimura, T., & Yamori, T. (2012) · Cancer Science · doi:10.1111/cas.12004 · Cited by 23
Kasper, M., & Toftgård, R. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.12.011 · Cited by 12
Cited by
Drug resistance in cancer: An overview
Housman, G., Byler, S., Heerboth, S., Lapinska, K., Longacre, M., Snyder, N., & Sarkar, S. (2014) · Cancers · doi:10.3390/cancers6031769 · Cited by 2,463
The Different Mechanisms of Cancer Drug Resistance: A Brief Review
Mansoori, B., Mohammadi, A., Davudian, S., Shirjang, S., & Baradaran, B. (2017) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2017.041 · Cited by 1,883
Oncogenic Role of Fusion-circRNAs Derived from Cancer-Associated Chromosomal Translocations
Guarnerio, J., Bezzi, M., Jeong, J. C., Paffenholz, S. V., Berry, K., Naldini, M. M., Lo-Coco, F., Tay, Y., Beck, A. H., & Pandolfi, P. P. (2016) · Cell · doi:10.1016/j.cell.2016.03.020 · Cited by 738
Emran, T. B., Shahriar, A., Mahmud, A. R., Rahman, T., Abir, M. H., Siddiquee, M. F. R., Ahmed, H., Rahman, N., Nainu, F., Wahyudin, E., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.891652 · Cited by 606
Theranostic Fluorescent Probes
Sharma, A., Verwilst, P., Li, M., Ma, D., Singh, N., Yoo, J., Kim, Y., Yang, Y., Zhu, J.-H., Huang, H., et al. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00778 · Cited by 499
Metadata
- Authors
- Zahreddine, H., & Borden, K. L. B.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2013
- Volume
- 4
- Pages
- 28-28
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2102099949
- Cited by
- 660
- References
- 147
- FWCI
- 14.54
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.